Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976864 | 0.90 | CXCR3 (0.51) | CXCR3HRH3KMT2AMEN1 | |
| SCHEMBL4976294 | 0.85 | MEN1 (0.54) | ALDH1A1HRH3KMT2AMEN1 | |
| SCHEMBL4976766 | 0.83 | HRH3 (0.47) | ALDH1A1CXCR3HRH3KDM4EKMT2A | |
| SCHEMBL4071423 | 0.83 | HRH1 (0.46) | ALDH1A1HRH3KDM4EKMT2AMEN1 | |
| SCHEMBL4980449 | 0.83 | MEN1 (0.43) | CXCR3HRH3KMT2AMEN1CFTR | |
| SCHEMBL4980684 | 0.82 | L3MBTL3 (0.47) | HRH3KMT2AMEN1 | |
| SCHEMBL4981995 | 0.81 | HRH1 (0.49) | ALDH1A1HRH3KDM4EKMT2AMEN1 | |
| SCHEMBL4976444 | 0.81 | MEN1 (0.43) | ALDH1A1CXCR3HRH3KDM4EKMT2A | |
| SCHEMBL4981943 | 0.78 | MEN1 (0.55) | ALDH1A1CXCR3HRH3KMT2AMEN1 | |
| SCHEMBL4980381 | 0.78 | MEN1 (0.40) | ALDH1A1CXCR3HRH3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| WO-2007146122-A2 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | ALDH1A1 1142/4885CHKA 850/4885CXCR3 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.